HSCT remains the only curative option for some hematologic disorders. However, it is associated with significant toxicities. The 100-day transplant-related mortality (TRM) may range from 3 to 10% and 20 to 50%, among autologous and allogeneic transplant recipients, respectively. We present the QMP’s favorable impact on our institution’s stem cell transplant outcomes. QMP reorganization was done pursuant to the Foundation for the Accreditation of Cellular Therapy (FACT) standards. Transplant-related aspects of care were identified and divided into 4 groups: clinical, data management, data collection, and financial. Members were expanded, and active participation from our Infectious Control service was solicited. Monthly audits of indicators from assigned aspect of care were conducted. Outcome analyses of data gathered from 2002 to 2004 were done. Internal and CIBMTR data served as benchmarks. Internal audit(s) revealed infection as the leading cause of early (<30 days) TRM among 9/16 patients who underwent allogeneic transplantation from September 2002 to December 2003, with documented bloodstream infection (BSI) in 55% of the patients. A significant increase in BSI during the fourth quarter of 2004 were noted among patients in the Cancer/HSCT services at 5.22 compared to 1.67/1000 patient days (internal benchmark). Clostridium difficile was increased in 2003, especially among HSCT recipients: 11.8 versus 3.6/1,000 pt days in 2002. Working in close collaboration with our Infectious Control service, contributory factors were identified and changes implemented to improve outcomes: construction of additional interventional radiology suite for central venous catheter placement, especially for immunocompromised patients, alteration of dressing change techniques, updating of infection control policies, and hiring of a dedicated transplant nurse practitioner. Follow-up data revealed a decrease of BSI to1.72/1,000 pt days in the first quarter 2005. C. difficile incidence trended down to 10/1000 pt days in 2004. The 2003 and 2004 100-day TRM showed significant decrease from 18% to 4% among autologous and 45% to 20% for allogeneic transplant recipients, respectively. Median neutrophil and platelet engraftments were 11.4 and 17 days for autologous transplants, and 16.5 and 21 days for allogeneic transplants, at par with CIBMTR data serving as benchmark. In summary, reorganization of our QMP favorably impacted our transplant practice. A multi-disciplinary approach is essential. HSCT remains the only curative option for some hematologic disorders. However, it is associated with significant toxicities. The 100-day transplant-related mortality (TRM) may range from 3 to 10% and 20 to 50%, among autologous and allogeneic transplant recipients, respectively. We present the QMP’s favorable impact on our institution’s stem cell transplant outcomes. QMP reorganization was done pursuant to the Foundation for the Accreditation of Cellular Therapy (FACT) standards. Transplant-related aspects of care were identified and divided into 4 groups: clinical, data management, data collection, and financial. Members were expanded, and active participation from our Infectious Control service was solicited. Monthly audits of indicators from assigned aspect of care were conducted. Outcome analyses of data gathered from 2002 to 2004 were done. Internal and CIBMTR data served as benchmarks. Internal audit(s) revealed infection as the leading cause of early (<30 days) TRM among 9/16 patients who underwent allogeneic transplantation from September 2002 to December 2003, with documented bloodstream infection (BSI) in 55% of the patients. A significant increase in BSI during the fourth quarter of 2004 were noted among patients in the Cancer/HSCT services at 5.22 compared to 1.67/1000 patient days (internal benchmark). Clostridium difficile was increased in 2003, especially among HSCT recipients: 11.8 versus 3.6/1,000 pt days in 2002. Working in close collaboration with our Infectious Control service, contributory factors were identified and changes implemented to improve outcomes: construction of additional interventional radiology suite for central venous catheter placement, especially for immunocompromised patients, alteration of dressing change techniques, updating of infection control policies, and hiring of a dedicated transplant nurse practitioner. Follow-up data revealed a decrease of BSI to1.72/1,000 pt days in the first quarter 2005. C. difficile incidence trended down to 10/1000 pt days in 2004. The 2003 and 2004 100-day TRM showed significant decrease from 18% to 4% among autologous and 45% to 20% for allogeneic transplant recipients, respectively. Median neutrophil and platelet engraftments were 11.4 and 17 days for autologous transplants, and 16.5 and 21 days for allogeneic transplants, at par with CIBMTR data serving as benchmark. In summary, reorganization of our QMP favorably impacted our transplant practice. A multi-disciplinary approach is essential.